Navigation Links
High and Super-High Potency Topical Corticosteroids Will Remain Decision Resources' Clinical Gold Standard Through 2017 for the Treatment of Atopic Dermatitis
Date:2/9/2009

A Once-Daily Topical Agent With a Novel Mechanism of Action and Efficacy Advantages Over Elidel Would Earn Higher Patient Share in the U.S. Than in Europe, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that high and super-high potency topical corticosteroids (TCSs) will remain Decision Resources' proprietary clinical gold standard through 2017 for the treatment of atopic dermatitis. While some therapies in development for the disease hold promise, most have efficacy, safety and tolerability and/or delivery issues.

"Although efficacious drugs like high and super-high potency TCSs are available, they are predominantly used to treat adult patients with severe atopic dermatitis," stated Kyle Crowell, analyst at Decision Resources. "For pediatric and adult patients with less severe atopic dermatitis, physicians prefer to prescribe drugs with superior safety profiles. Improvements in safety and tolerability would provide a competitive advantage for an emerging atopic dermatitis drug."

The new report entitled Atopic Dermatitis: A Market with Well-Established First-Line Agents Still Needs a Safe Maintenance Therapy also finds that a once-daily topical agent with a novel mechanism of action and efficacy advantages over Novartis' Elidel would earn 35 percent patient share in the atopic dermatitis drug market, according to surveyed U.S. dermatologists. On the other hand, in Europe, such an agent would earn a 25 percent patient share, according to surveyed European dermatologists.

About the Report

Atopic Dermatitis: A Market with Well-Established First-Line Agents Still Needs a Safe Maintenance Therapy is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Natalia Morales                        Elizabeth Marshall
    Decision Resources                     Decision Resources, Inc.
    781-296-2691                           781-296-2563
    nmorales@dresources.com                emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site
2. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
3. Bariatric Advantage Announces New Higher-Potency Iron Supplement for Weight Loss Surgery Patients
4. Novel molecules developed at UB can boost vaccine potency
5. Nordic Naturals Professional Exclusive Division Redefines High Potency Omega-3 Supplementation With New Elite Line!
6. Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
7. Ready-To-Use Products Spur the European Tissue Sealants and Topical Hemostats Markets, Says Frost & Sullivan
8. New topical approach to treating nail fungus circumvents problems with current therapy
9. Topical treatment for cold sores achieves efficacy of oral drugs; represents paradigm shift
10. Topical oral syrup prevents early childhood caries
11. Nuvo licenses topical pain product from Paladin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... ... large animal healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, ... development and joint health in horses at the immunologic level. , The scientifically-developed ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a ... new strategies to reduce waste, and support renewable energy. They believe this is a ... nature to find solutions for health issues, and maintain that destroying the environment in ...
(Date:4/24/2017)... ... ... The bar for just about everything—apparel, eyewear, cars and even phone cases—is ... and film stardom.(1) Not to be left out is that most desired of commodities, ... gamut from being encrusted with jewels and precious metals to, at the very least, ...
(Date:4/24/2017)... ... ... Sean Fay is the undisputed king of the infomercial. With clients as ... Foreman Grill (which sold more than 100 million units worldwide), he has created more ... due to changes in the broadcast media landscape, the once ever-present infomercial has gone ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
Breaking Medicine Technology: